Fluent BioSciences v3.0 Kits Now Shipping with Nuclei Compatibility

News

Fluent BioSciences launches industry’s most accessible, cost-effective and scalable technology (PIPseq™) to accelerate adoption of single-cell RNA sequencing in any laboratory

Priced as low as $300 per reaction, the T2 and T20 kits enable any researcher to immediately access the power of single-cell transcriptomics with no capital investment WATERTOWN, Mass., June 23, 2022 /PRNewswire/ — Fluent BioSciences, a biotechnology company focused on making single-cell analysis simple and accessible to every researcher, announced the launch of two new breakthrough products for […]

Read More

Fluent BioSciences and NanoCellect announce joint collaboration to improve resolution of single-cell RNA sequencing analysis of rare cell populations

Watertown, MA, June 17, 2022 – Fluent BioSciences, a biotechnology company focused on making single-cell analysis simple and accessible to every researcher, and NanoCellect Biomedical, Inc., a leader in the development and manufacturing of innovative and affordable solutions for cell sorting, jointly announced a collaboration to improve resolution and efficiency of single-cell RNA sequencing (scRNA-seq) […]

Read More

Fluent BioSciences expands access to industry’s most flexible and scalable technology (PIPseq) to enable sensitive single-cell transcriptome analysis in any laboratory

Watertown, MA., May 5, 2022 – Fluent BioSciences, a biotechnology company focused on making single-cell analysis simple and accessible to every researcher, announced expanded early access to two new products for 3′ single-cell RNA analysis. Scaled to efficiently and effectively meet diverse experimental demands, PIPseqTM T2 and T20 kits capture up to 2,000 and 20,000 […]

Read More

Fluent BioSciences awarded $1.7 Million SBIR grant to commercialize PIPseq™ a breakthrough platform technology enabling scalable, sensitive single-cell analysis in any laboratory

Funding will be used to support commercialization of single-cell RNA sequencing (scRNA-Seq) products and services to address the critical need for accessibility, affordability and scalability. Watertown, MA., March 9, 2022 – Fluent BioSciences, a biotechnology company focused on making single-cell analysis simple and accessible to every researcher, announced today that it has been awarded a […]

Read More